{"title":"Association of Meteorological Factors and Air Pollutants With Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis.","authors":"Huike Feng, Wangyang Gu, Qingpeng Li, Yihao Xue, Linling Xu, Shilu Tong, Shijian Liu","doi":"10.1177/17103568261447486","DOIUrl":"https://doi.org/10.1177/17103568261447486","url":null,"abstract":"<p><p>There is no consensus on the impact of meteorological factors and air pollutants on childhood atopic dermatitis (AD). Literature was searched in 3 databases (PubMed, Web of Science, and Embase) up to May 1, 2025, and evaluated by 2 independent reviewers. Cross-sectional studies, cohort studies, or time-series analyses were included, reporting outcomes of meteorological factors, air pollutants, and childhood AD. The Newcastle-Ottawa Scale and Agency for Healthcare Research and Quality scale were used to assess study quality. A random-effects model was applied to estimate pooled risk ratios. From 132 identified literature, 49 studies involving nearly 7,091,746 participants were included. Air pollutants were positively correlated with the risk of childhood AD (odds ratio [OR] [95% confidence interval or CI] = 1.030 [1.005, 1.056] for carbon monoxide [CO]; 1.116 [1.075, 1.264] for nitrogen dioxide [NO<sub>2</sub>]; 1.059 [1.013, 1.108] for ozone; 1.114 [1.039, 1.260] for particulate matter [PM] with diameter of 10 µm [PM<sub>10</sub>]; 1.041 [1.009, 1.074] for PM with diameter of 2.5 µm [PM<sub>2.5</sub>]). No clear associations were observed between sulfur dioxide, temperature, humidity, and ultraviolet radiation (UVR) and the risk of childhood AD. Subgroup analysis showed that higher temperature and UVR might reduce the risk of AD, increased concentrations of CO, NO<sub>2</sub> in developed countries, and PM<sub>10</sub>, PM<sub>2.5</sub>, and NO<sub>2</sub> might increase the incidence risk in developing countries. Air pollutants represented significant risk factors for childhood AD, underscoring the imperative to prioritize environmental quality improvement for AD prevention.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261447486"},"PeriodicalIF":3.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maddalena Napolitano, Giuseppe Lauletta, Martina Turco, Valeria Boccaletti, Laura Diluvio, Luca Bianchi, Greta Tronconi, Mattia Giovannini, Michela Ortoncelli, Samantha Federica Berti, Cristina Guerriero, Daniele Omar Traini, Elena Pezzolo, Elettra Antonelli, Luca Stingeni, Elia Esposto, Carla Mastrorilli, Vincenzo Piccolo, Maria Letizia Musumeci, Alan Azzolini, Paola Zangari, Filomena Russo, Barbara Cocuroccia, Iorio Carmela, Vito Di Lernia, Sticchi Alberto, Alessandra Grazia Condorelli, Mariavalentina Catania, Emilia Cirillo, Cataldo Patruno, Miriam Leuzzi, Alessandra Gelmetti, Iria Neri
{"title":"Real-Life Effectiveness, Safety, and Growth Outcomes of Dupilumab in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Study from an Italian NPP Program.","authors":"Maddalena Napolitano, Giuseppe Lauletta, Martina Turco, Valeria Boccaletti, Laura Diluvio, Luca Bianchi, Greta Tronconi, Mattia Giovannini, Michela Ortoncelli, Samantha Federica Berti, Cristina Guerriero, Daniele Omar Traini, Elena Pezzolo, Elettra Antonelli, Luca Stingeni, Elia Esposto, Carla Mastrorilli, Vincenzo Piccolo, Maria Letizia Musumeci, Alan Azzolini, Paola Zangari, Filomena Russo, Barbara Cocuroccia, Iorio Carmela, Vito Di Lernia, Sticchi Alberto, Alessandra Grazia Condorelli, Mariavalentina Catania, Emilia Cirillo, Cataldo Patruno, Miriam Leuzzi, Alessandra Gelmetti, Iria Neri","doi":"10.1177/17103568261448380","DOIUrl":"https://doi.org/10.1177/17103568261448380","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world evidence on the long-term use of dupilumab in very young children with moderate-to-severe atopic dermatitis (AD) remains limited. Observational data are needed to complement clinical trial findings by describing treatment outcomes in routine clinical practice.</p><p><strong>Methods: </strong>This multicenter retrospective study included children aged 6 months to 5 years with moderate-to-severe AD treated with dupilumab through the Italian Named Patient Program. Clinical assessments were performed at baseline and at weeks (W) 16, 24, 36, and 52. Disease severity, quality of life, and symptom burden were evaluated using the Eczema Area and Severity Index (EASI), Children's Dermatology Life Quality Index (c-DLQI), pruritus-numeric rating scale (P-NRS), and sleep-numeric rating scale (S-NRS). EASI-50/75/90 responder rates were calculated at each time point. Safety data were collected throughout treatment. Growth parameters were monitored between baseline and W52.</p><p><strong>Results: </strong>Forty-seven children were included. Dupilumab led to rapid and progressive improvement of AD severity, with mean EASI decreasing from 26.1 at baseline to 2.7 at W52 (-89.7%). Marked improvements were also observed in quality of life (-91.3% in c-DLQI), itch intensity (-82.5% in P-NRS), and sleep disturbance (-82.7% in S-NRS). At W52, EASI-75 and EASI-90 responses were achieved by 79.5% and 59.0% of evaluable patients, respectively. Dupilumab was well tolerated, with treatment-emergent adverse events occurring in 10.6% of patients, all mild or moderate and none leading to discontinuation. Weight- and height-for-age <i>z</i>-scores significantly increased over 52 weeks; no child newly developed values below -2 standard deviations, although 1 child remained below this threshold at W52. Percentile-based analyses yielded consistent results, confirming the absence of negative effects on growth.</p><p><strong>Conclusion: </strong>Dupilumab was effective and well tolerated over 52 weeks in children aged 6 months to 5 years with moderate-to-severe AD, providing sustained skin clearance, symptom relief, and quality-of-life improvement. These findings support dupilumab as a valuable long-term therapeutic option in very young children with uncontrolled AD in clinical practice.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261448380"},"PeriodicalIF":3.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"<i>Letter:</i> Is There Cross-Reactivity Between Sorbitan Sesquioleate and Sorbic Acid?","authors":"Divya R Alley, Hani Abi, Anne Neeley","doi":"10.1177/17103568261448927","DOIUrl":"https://doi.org/10.1177/17103568261448927","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261448927"},"PeriodicalIF":3.2,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147847820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mihir M Shah, Eri Fukaya, Golara Honari, Jennifer K Chen, Gordon H Bae
{"title":"Clinical Spectrum of Hypersensitivity and Granulomatous Reactions to VenaSeal<sup>™</sup> Cyanoacrylate Closure.","authors":"Mihir M Shah, Eri Fukaya, Golara Honari, Jennifer K Chen, Gordon H Bae","doi":"10.1177/17103568261446233","DOIUrl":"https://doi.org/10.1177/17103568261446233","url":null,"abstract":"<p><strong>Introduction: </strong>The VenaSeal<sup>™</sup> Closure System uses n-butyl-2-cyanoacrylate for minimally invasive treatment of chronic venous disease. While generally safe, reported adverse events include phlebitis, hypersensitivity, foreign body granulomas, and endovenous glue-induced thrombosis. Specifically, hypersensitivity reactions have been reported in 6.3%-13% of patients.</p><p><strong>Methods: </strong>We present 4 patients with heterogeneous cutaneous and systemic reactions following CAC, ranging from localized nodules to erythroderma. Diagnostic evaluation included patch testing, ultrasound, CT, and histopathology, with varying findings for each case.</p><p><strong>Results: </strong>Consequently, treatments ranged from intralesional corticosteroids to prolonged systemic corticosteroids and surgical excision.</p><p><strong>Conclusion: </strong>This case series highlights the limitations of patch testing, the importance of considering imaging and biopsy for diagnosis, and the need for individualized management strategies.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261446233"},"PeriodicalIF":3.2,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tara Ghalambor, Elena Bigliardi, Benjamin Buttars, Claudia Lang, Peter Schmid-Grendelmeier, Dathan Hamann
{"title":"Noninvasive Imaging Modalities for Evaluating Patch Testing: A Systematic Review.","authors":"Tara Ghalambor, Elena Bigliardi, Benjamin Buttars, Claudia Lang, Peter Schmid-Grendelmeier, Dathan Hamann","doi":"10.1177/17103568261445179","DOIUrl":"https://doi.org/10.1177/17103568261445179","url":null,"abstract":"<p><p>Despite being the gold standard for diagnosing allergic contact dermatitis (ACD), interpretation of patch test reactions remains subjective, relying heavily on visual assessment and palpation. This presents challenges when distinguishing between doubtful, weak allergic, and irritant reactions, particularly in patients with skin of color, where erythema may be less apparent. Recent updates to the International Contact Dermatitis Research Group (ICDRG) classification system underscore the need to refine criteria for more consistent interpretation and to improve assessment methods across diverse skin types. Noninvasive imaging technologies offer promising alternatives to traditional visual grading by enabling objective characterization of patch test reactions. In this systematic review, we assess 38 studies investigating various modalities, including ultrasound, thermography, optical coherence tomography, reflectance confocal microscopy, and 3D imaging systems. Each modality was evaluated for its mechanism, measurable variables, alignment with ICDRG criteria, ease of use, and ability to differentiate patch test reaction grades. While several tools demonstrated potential in identifying positive reactions, many were limited to binary classification and lacked validation in diverse populations. Integration into clinical practice remains limited by cost, training, and variability in data interpretation. Further research incorporating the updated ICDRG guidelines and broader representation of skin tones is essential to determine the utility of these modalities. Improving objectivity in patch test evaluation may ultimately lead to more equitable and accurate diagnosis of ACD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261445179"},"PeriodicalIF":3.2,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maha Lahouel, Maryem Mhiri, Sana Mokni, Nejet Ghariani, Mohamed Denguezli
{"title":"<i>Letter:</i> When Patch Testing Is Not Enough: The Contribution of Food-Specific IgE in Allergic Contact Cheilitis.","authors":"Maha Lahouel, Maryem Mhiri, Sana Mokni, Nejet Ghariani, Mohamed Denguezli","doi":"10.1177/17103568261448310","DOIUrl":"https://doi.org/10.1177/17103568261448310","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261448310"},"PeriodicalIF":3.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147824903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael J Diaz, Jasmine T Tran, Kamil Taneja, Kelly Tyler, Dathan Hamann
{"title":"<i>Letter:</i> Emergency Department Charges Associated With Contact Dermatitis in the USA: A Retrospective Analysis of 121,460 Visits.","authors":"Michael J Diaz, Jasmine T Tran, Kamil Taneja, Kelly Tyler, Dathan Hamann","doi":"10.1177/17103568261433361","DOIUrl":"https://doi.org/10.1177/17103568261433361","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"17103568261433361"},"PeriodicalIF":3.2,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}